Document Detail


Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein.
MedLine Citation:
PMID:  19934105     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Familial Mediterranean fever (FMF) is caused by mutations in MEFV, which encodes pyrin. The nature of substitutions P369S and R408Q in exon 3 remains unclear. Exon 3 encoding pyrin's B-box domain is necessary for interactions with proline serine threonine phosphatase interacting protein 1 (PSTPIP1). The aim was to characterise the phenotype of patients with these substitutions and to determine their functional significance.
METHODS: A database of genetic tests undertaken at the US National Institutes of Health was interrogated. Symptoms and signs were classified according to Tel-Hashomer criteria. Coimmunoprecipitation techniques were employed to determine the variants' effects on pyrin/PSTPIP1 interactions.
RESULTS: A total of 40 symptomatic and 4 asymptomatic family members with these substitutions were identified. P369S and R408Q were found in cis, and cosegregated in all patients sequenced. Clinical details were available on 22 patients. In all, 5 patients had symptoms and signs fulfilling a clinical diagnosis of FMF, and 15 received colchicine. In patients not achieving the criteria, trials of anti-tumour necrosis factor (TNF) agents resulted in partial or no benefit; resolution of symptoms was noted in those receiving anakinra. The carrier frequency was higher in the patient cohort than in controls but was not statistically significant. Coimmunoprecipitation studies demonstrated that these pyrin variants did not affect binding to PSTPIP1.
CONCLUSIONS: P369S/R408Q substitutions are associated with a highly variable phenotype, and are infrequently associated with typical FMF symptoms, however a trial of colchicine is warranted in all. Functional and modelling studies suggest that these substitutions do not significantly affect pyrin's interaction with PSTPIP1. This study highlights the need for caution in interpreting genetic tests in patients with atypical symptoms.
Authors:
J G Ryan; S L Masters; M G Booty; N Habal; J D Alexander; B K Barham; E F Remmers; K S Barron; D L Kastner; I Aksentijevich
Related Documents :
19667225 - Atypical progressive multifocal leukoencephalopathy associated with an unusual jc polyo...
2177715 - Effect of chronic administration of verapamil in duchenne muscular dystrophy.
8625045 - Microsatellite instability in keratoacanthoma.
8390325 - Congenital endplate acetylcholinesterase deficiency.
2921145 - Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and ...
21320835 - The neuropathies of waldenström's macroglobulinemia (wm) and igm-mgus.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2009-11-23
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  69     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-22     Completed Date:  2010-07-27     Revised Date:  2013-04-12    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1383-8     Citation Subset:  IM    
Affiliation:
National Institute of Arthritis and Musculoskeletal and Skin Diseases, Building 10, Magnuson Clinical Center, 10C101C, Bethesda, Maryland 20892, USA. johngryan@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age of Onset
Child
Child, Preschool
Colchicine / therapeutic use
Cytoskeletal Proteins / genetics*
Familial Mediterranean Fever / diagnosis,  drug therapy,  genetics*
Genetic Predisposition to Disease
Genotype
Humans
Infant
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Middle Aged
Mutation*
Retrospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Young Adult
Grant Support
ID/Acronym/Agency:
Z01 AR041083-18/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Cytoskeletal Proteins; 0/Interleukin 1 Receptor Antagonist Protein; 0/Tumor Necrosis Factor-alpha; 0/marenostrin; 64-86-8/Colchicine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gen...
Next Document:  Mitochondrial DNA haplogroups modulate the serum levels of biomarkers in patients with osteoarthriti...